Survey of Ophthalmology
Volume 49, Issue 2, Supplement 2 , Pages S79-S83 , March 2004

Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones

  • David G. Hwang, MD, FACS

      Affiliations

    • Corresponding Author InformationReprint address: David G. Hwang, MD, FACS, Cornea Service, Department of Ophthalmology, University of California, San Francisco, San Francisco, California USA 94143-0730.

References 

  1. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497–1502
  2. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:433–438
  3. Boswell FJ, Andrews JM, Jevons G, Wise R. Comparison of in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother. 2002;50:495–502
  4. Chaudhry NA, Flynn HW, Murray TG, et al.  Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999;128:509–510
  5. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis. 2003;22:203–221
  6. Goldstein MH, Kowalski RP, Gordon J. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106:1313–1318
  7. Kowalski RP, Dhaliwal DK, Karenchak LM, et al.  Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500–505
  8. Leeming JP. Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet. 1999;37:351–360
  9. Liesegang TJ. Use of antimicrobials to prevent postoperative infection in patients with cataracts. Curr Opin Ophthalmol. 2001;12:68–74
  10. Liesegang TJ. Prophylactic antibiotics in cataract operations. Mayo Clin Proc. 1997;72:149–159
  11. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463–466
  12. O'Brien TP, Maquire MG, Fink NE, et al.  Efficacy of ofloxacin versus cefazolin and tobramycin in the therapy of bacterial keratitis. Report from the Bacterial Keratitis Research Group. Arch Ophthalmol. 1995;113:1257–1265
  13. Saravoltz L, Manzor O, Check C, et al.  Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother. 2001;47:875–877
  14. Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones. Place in ocular therapy. Drugs. 2001;61:747–761
  15. Watanabe K, Numata-Watanabe K, Hayasaka S. Methicillin-resistant staphylococci and ofloxacin-resistant bacteria from clinically healthy conjunctivas. Ophthalmic Res. 2001;33:136–139
  16. Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al.  0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. Arch Ophthalmol. 1993;111:1210–1218
  17. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001;33(Suppl 3):S147–S156

☆ The author reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

PII: S0039-6257(04)00005-0

doi: 10.1016/j.survophthal.2004.01.004

Survey of Ophthalmology
Volume 49, Issue 2, Supplement 2 , Pages S79-S83 , March 2004

Article Tools